The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

During the 2019 International Society of Urological Pathology Consultation Conference on
Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented …

… Author contributions: Joshua I. Warrick had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data analysis. …

Molecular subtyping has been a major focus of bladder cancer research over the past decade.
Despite many promising associations with clinical outcomes and treatment response, its …

Pathologists have identified many “histologic variants” of bladder cancer (BCA): histologic
patterns that differ from conventional urothelial carcinoma (transitional cell carcinoma). …

Discrete bladder cancer molecular subtypes exhibit differential clinical aggressiveness and
therapeutic response, which may have significant implications for identifying novel …

Human cancers display a restricted set of expression profiles, despite diverse mutational
drivers. This has led to the hypothesis that select sets of transcription factors act on similar …

Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of
urothelial carcinoma adjacent to or admixed with regions of divergent histomorphology, most …

Ovarian cancer remains the most lethal gynecologic malignancy, and is primarily diagnosed
at late stage when considerable metastasis has occurred in the peritoneal cavity. At late …

Although advanced bladder cancer overall has a poor prognosis, a subset of patients demonstrate
durable response to immune checkpoint inhibitors. Evidence shows that the response …